SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?


To: grayhairs who wrote (21)10/17/2000 7:50:13 AM
From: Gulo  Read Replies (1) | Respond to of 103
 
You're not dreaming.

The main limitation I see is that many people have a natural immunity to the virus (prior exposure). As an adjunct to mild chemotherapy, the virus has great potential.
In a best case scenario, all that would be required is to suppress the immune system a bit so that the virus can propagate and reach mestastases.

I would really like to know how the toxicity (Phase I) study is going.

-g